JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. today announced that Mr. Eli Hurvitz, the Chairman of the Company’s Board of Directors, has responded successfully to therapy for a recently diagnosed illness. Mr. Hurvitz is taking a leave of absence of approximately three weeks in order to allow for recuperation from his treatment. During this time, Professor Moshe Many, a long-time member of the Board, will temporarily stand in for Mr. Hurvitz as Chairman of the Board.
We wish Mr. Hurvitz a speedy recovery and anticipate his prompt return to his normal routine.
About Teva
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva’s sales are in North America and Western Europe.
Contact:
Teva Pharmaceutical Industries Ltd. Elana Holzman, 972 (3) 926-7554 or Teva North America Kevin Mannix, 215-591-8912 www.tevapharm.com
